ViroGates A/S

ViroGates A/S Debt

The Debt of ViroGates A/S (VIRO.CO) as of Nov 22, 2026 is 4.62 M DKK. In the previous year, Debt was 5.30 M DKK — a change of -12.77% (lower).

Debt

4.62 MDKK

YoY

-12.77%

Last updated:

In 2025, ViroGates A/S's total debt was 4.62 M DKK, a -12.77% change from the 5.30 M DKK total debt recorded in the previous year.

The ViroGates A/S Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2016
0.00 DKK
Jan 1, 2017
0.00 DKK
Jan 1, 2022
0.00 DKK
Jan 1, 2023
5.30 M DKK
Jan 1, 2024
5.30 M DKK
Jan 1, 2025
4.62 M DKK
The ViroGates A/S Debt history
YEARDebtYoY
4.62 MDKK-12.77%
5.30 MDKK0.00%
5.30 MDKK—
0.00DKK—
0.00DKK—
0.00DKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViroGates A/S Stock analysis

What does ViroGates A/S do? ViroGates A/S develops and markets prognostic products for the healthcare sector, focusing on the suPARnostic product line that measures soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The suPARnostic Quantitative Point of Care Quick Triage test is designed for patient triage in acute care settings, while the Quantitative ELISA Assay targets clinical routine use. Healthcare providers, including hospitals and clinics, purchase these products to assess immune activation levels and monitor disease progression, particularly for conditions like HIV-1-infection, malaria, tuberculosis, and sepsis. The company generates revenue through the sale of these diagnostic tools to healthcare institutions for use in patient care and disease management. The suPARnostic product line serves as a marker for survival chances upon hospital admission and aids in early intervention by detecting elevated suPAR levels linked to increased inflammation and mortality risk. High suPAR levels are associated with infectious diseases such as Streptococcus pneumonia bacteraemia, pneumococcal pneumonia, and bacterial and viral CNS infections. Healthcare facilities utilize the quantitative tests to determine patient prognosis and guide treatment decisions, ensuring timely interventions that improve patient outcomes. ViroGates A/S monetizes its diagnostic solutions by supplying healthcare systems with tools that enhance clinical decision-making and patient monitoring capabilities. ViroGates A/S targets healthcare providers who require rapid and accurate diagnostic tools for acute care and routine clinical use. The company's products are specifically tailored for monitoring immune activation in patients with infectious diseases, offering both point-of-care testing and laboratory-based assays. By providing these specialized diagnostic solutions, ViroGates A/S supports healthcare institutions in managing patient care more effectively, leading to better health outcomes and reduced mortality rates. Revenue is derived from the direct sale of suPARnostic tests to hospitals, clinics, and other clinical facilities that integrate these tools into their diagnostic workflows. ViroGates A/S is one of the most popular companies on Eulerpool.

Debt Details

Understanding ViroGates A/S's Debt Structure

ViroGates A/S's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing ViroGates A/S's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to ViroGates A/S’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in ViroGates A/S’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about ViroGates A/S stock

Debt of ViroGates A/S is 4.62 M DKK in 2025.

Debt of ViroGates A/S changed from 5.30 M DKK to 4.62 M DKK, representing a -12.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt ViroGates A/S since 2006 – with annual values, charts, and detailed analysis.

Debt's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's ViroGates A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ViroGates A/S

All Key Metrics — ViroGates A/S